CD41a Monoclonal Antibody (HIP8), eBioscience™, Invitrogen™

Description

Description: The HIP8 monoclonal antibody reacts with the human CD41 molecule, the integrin alphaIIb also known as platelet GPIIb. CD41 non-covalently associates with integrin beta3 (GPIIIa, CD61) and is expressed by megakaryocytes and platelets. The CD41/CD61 complex is a receptor for fibronectin, fibrinogen, von Willebrand factor, vitronectin and thrombospondin and mediates platelets aggregation. HIP8 blocks platelet aggregation. Applications Reported: The HIP8 antibody has been reported for use in flow cytometric analysis, and immunohistochemical staining. Applications Tested: The HIP8 antibody has been tested by flow cytometric analysis of human platelets. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

CD41 (platelet glycoprotein IIb, ITGA2B) is composed of two subunits -120 kDa a, alpha and 23 kDa b, beta- that interact with CD61 in the presence of calcium to form a functional adhesive protein receptor. CD41 is also involved in blood coagulation by mediating platelet aggregation. Upon blood vessel damage, CD41 binds to a variety of proteins including von Willebrand factor, fibrinogen, fibronectin and vitronectin. CD41 is mainly expressed on megakaryocyte-platelet lineage, but generally belongs to the antigens that are expressed during the early stages of hematopoietic differentiation. Diseases associated with CD41 dysfunction include Glansmann Thrombasthenia, and Platelet type-16 bleeding disorder.